A randomized trial of fistula VS. Graft arteriovenous vascular access in older adults with end-stage kidney disease on hemodialysis: the AV access trial

Active Project Grant Awarded Last action

Award ID
R01AG071803
Recipient
Awarding agency
Obligated
$9,414,395

Award facts

Assistance listing
93.866 Aging Research
Completion date 86% complete
Originally
Funding
  • $8,124,073.00 Federal
  • $1,290,322.00 Non-federal
Place of performance
Winston-Salem, NC 27157, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
End-stage kidney disease is a disease of aging, exacerbated by multiple coexisting health conditions. Nearly 50% of patients initiating chronic hemodialysis for treatment of end-stage kidney disease are 65 years or older. Patients who use central venous catheters for hemodialysis access typically undergo surgical placement of an arteriovenous access-either a fistula or a graft-to reduce the risks of infection, vascular complications and death associated with catheter use. Arteriovenous fistulas have long been considered first-line vascular access option, with grafts as second best. However, several recent studies suggest that grafts may be a better strategy than fistulas for hemodialysis access in older adults. Without evidence from well-powered randomized clinical trials, these studies cannot be integrated into practice. We conducted the first pilot trial (n=46) that revealed the feasibility of enrolling and randomizing older adults to surgical fistula or graft placement, with 89% (20 of 22) of those assigned to fistula and 79% (19 of 24) of those assigned to graft placement undergoing the assigned intervention. Building on this successful pilot, we propose a pragmatic multicenter randomized clinical trial in 262 adults, 65 years of age and older, receiving hemodialysis via catheters. Unbiased, comparative characterization of clinical outcomes and patient views between alternative access strategies will advance the field, for the first time, to evidence-based vascular access care. Our long-term goals are to optimize clinical decisions based on objective, age-specific data while incorporating goals of care and patient preference for vascular access type. The objective of this proposal is to delineate vascular access effects on disease-specific and patient-reported outcomes, using a randomized intervention, at 6 national sites, of surgical fistula versus graft placement in older adults who have end-stage kidney disease and coexisting coronary artery disease, peripheral arterial disease, and/or diabetes mellitus. The overarching hypothesis is that graft placement strategy will yield more dialysis catheter-free days, lower cost, and better patient satisfaction. Our specific aims will determine the effects of fistula versus graft vascular access strategy on rates of catheter-free dialysis days and access-related infections and death (primary aim), costs associated with vascular access care (secondary aim), and patient-reported satisfaction with access-related outcomes (tertiary aim). We will also investigate the relationship between preoperative objective and subjective measures of physical function and failure of fistula or graft maturation (exploratory aim). Results from this trial could transform the clinical practice by providing high-quality evidence to guide common clinical decisions on dialysis vascular access in older adults-a growing population whose care is complex and costly.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $828,855 $0
Amendment $1,016,814 $0
Amendment $1,191,406 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,253,177 $0
Amendment $1,253,177 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $1,290,322 $0
Original award $1,290,322 $1,290,322
Show all 14

Subawards

Subrecipient Amount Awarded
Prisma Health - Upstate "The Vascular Access Surgery group of Prisma Health-Upstate, Greenville, SC, will coordinate local site management of this multi-site randomized clinical… $49,100
Prisma Health - Upstate "The Vascular Access Surgery group of Prisma Health- Upstate, Greenville, SC, will coordinate local site management of this multi-site randomized clinical trial… $60,000

Quick answers

Who received award R01AG071803?

R01AG071803 was awarded to Wake Forest University Health Sciences by National Institute on Aging (National Institutes of Health) on September 1, 2021.

How much is award R01AG071803 worth?

$9,414,395 has been obligated on R01AG071803: $8,124,073 in federal funding and $1,290,322 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login